3.8 Review

Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia

期刊

FUTURE CARDIOLOGY
卷 1, 期 1, 页码 39-59

出版社

FUTURE MEDICINE LTD
DOI: 10.1517/14796678.1.1.39

关键词

adipose autodysharmonia; adiposopathy diabetes; Food and Drug Administration; hypertension; obesity metabolic cycle; metabolic syndrome; obesity; regulatory

资金

  1. Alteon
  2. Aventis
  3. Bayer
  4. Boehringer Ingelheim
  5. Boehringer Mannheim
  6. Bristol-Myers Squibb
  7. Fujisawa
  8. Ciba-Geigy
  9. GelTex
  10. Glaxo
  11. Genetech
  12. Hoechst Roussel
  13. KOS
  14. Lederle
  15. Marion Merrell Dow
  16. Merck
  17. Merck Schering-Plough
  18. Miles
  19. Novartis
  20. Parke-Davis
  21. Pfizer
  22. Purdue
  23. Reliant
  24. Roche
  25. Rorer
  26. Regeneron
  27. Sandoz
  28. Sankyo
  29. Sanofi
  30. Shering Plough
  31. Searle
  32. SmithKline Beacham
  33. Takeda
  34. TAP
  35. UpJohn
  36. Upsher Smith
  37. Warner-Lambert
  38. Wyeth-Ayerst
  39. AstraZenca
  40. NIH [K23-RR16075]
  41. NIH/DHS/DHHS [MO1-RR-00633]
  42. CDC [H75/CCH523202]
  43. AHA [0465017Y]

向作者/读者索取更多资源

Adiposopathy is defined as pathological adipose tissue function that may be promoted and exacerbated by fat accumulation (adiposity) and sedentary lifestyle in genetically susceptible patients. Adiposopathy is a root cause of some of the most common metabolic diseases observed in clinical practice, including Type 2 diabetes mellitus, hypertension and dyslipidemia. The most common term for the metabolic consequences of adiposopathy is currently 'the metabolic syndrome'. Drug usage to treat the metabolic syndrome has focused on the safety and efficacy of treatments directed towards individual components of the metabolic syndrome, and not so much upon adiposopathy itself. However, enough is known about the pathophysiology of adiposopathy to propose diagnostic criteria. Regulatory issues are important obstacles to the research and development of new drug treatments for the metabolic syndrome. It is hoped that these obstacles can, to some extent, be addressed and overcome by clearly defining and increasing our understanding of adiposopathy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据